UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

Annals of oncology, 2019-04, Vol.30 (4), p.558-566

2019

Volltextzugriff (PDF)

Identifying well-bleached quartz using the different bleaching rates of quartz and feldspar luminescence signals

Radiation measurements, 2012-09, Vol.47 (9), p.688-695

2012

Volltextzugriff (PDF)

A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer

Annals of oncology, 2012-06, Vol.23 (6), p.1441-1448

2012

Volltextzugriff (PDF)

Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer

Annals of oncology, 2017-04, Vol.28 (4), p.754-760

2017

Volltextzugriff (PDF)

Multicenter Randomized Open-Label Phase II Clinical Study Comparing Outcomes of NK105 and Paclitaxel in Advanced or Recurrent Breast Cancer

International journal of nanomedicine, 2022-01, Vol.17, p.4567-4578

2022

Volltextzugriff (PDF)

Safety profile and effectiveness of alectinib in the real-world surveillance study of 1251 Japanese patients with ALK-positive non-small cell lung cancer

Annals of oncology, 2018-10, Vol.29, p.viii502-viii502

2018

Volltextzugriff (PDF)

A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer

Cancer chemotherapy and pharmacology, 2014-08, Vol.74 (2), p.229-238

2014

Volltextzugriff (PDF)

Chaotic block ciphers: from theory to practical algorithms

IEEE transactions on circuits and systems. 1, Fundamental theory and applications, 2006-06, Vol.53 (6), p.1341-1352

2006

Volltextzugriff (PDF)

Substrate Specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM Efflux Pumps in Pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy, 2000-12, Vol.44 (12), p.3322-3327

2000

Volltextzugriff (PDF)

The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study

Annals of oncology, 2011-08, Vol.22 (8), p.1777-1782

2011

Volltextzugriff (PDF)

Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: Updated results from a phase I/II trial

Annals of oncology, 2019-05, Vol.30, p.iii48-iii48

2019

Volltextzugriff (PDF)

346P Phase I study of the liposomal formulation of eribulin (E7389-LF): Results from the HER2-negative breast cancer expansion

Annals of oncology, 2020-09, Vol.31, p.S385-S385

2020

Volltextzugriff (PDF)

Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial

Breast cancer (Tokyo, Japan), 2018-07, Vol.25 (4), p.407-415

2018

Volltextzugriff (PDF)

Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy

Breast cancer research and treatment, 2013-11, Vol.142 (1), p.69-80

2013

Volltextzugriff (PDF)

Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1)

Annals of oncology, 2010-12, Vol.21 (12), p.2342-2347

2010

Volltextzugriff (PDF)

Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples

Nucleic acids research, 1999-11, Vol.27 (22), p.4436-4443

1999

Volltextzugriff (PDF)

Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari)

Breast cancer research and treatment, 2017-06, Vol.163 (3), p.545-554

2017

Volltextzugriff (PDF)

A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer

Annals of oncology, 2017-02, Vol.28 (2), p.285-291

2017

Volltextzugriff (PDF)

A phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in elderly patients with advanced stage HER2-positive breast cancer (JCOG1607 HERB TEA study)

Annals of oncology, 2018-10, Vol.29, p.viii118-viii118

2018

Volltextzugriff (PDF)

Distant disease-free survival (DDFS) according to response category in neoadjuvant endocrine therapy (NET): 6-year analysis in phase III NEOS trial

Annals of oncology, 2018-10, Vol.29, p.viii58-viii58

2018

Volltextzugriff (PDF)

Abstract PD1-03: Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: Updated results of a phase 1/2 trial

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.PD1-03-PD1-03

2019

Volltextzugriff (PDF)

Effect of dose timing on the blood concentration of lapatinib in patients with breast cancer

Annals of oncology, 2017-11, Vol.28 (11), p.2888-2889

2017

Volltextzugriff (PDF)

Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3

Annals of oncology, 2018-10, Vol.29, p.viii708-viii708

2018

Volltextzugriff (PDF)

Clinical efficacy of eribulin as first- or second-line treatment for patients with recurrent HER2-negative breast cancer: A phase II randomized study (JBCRG-19)

Annals of oncology, 2018-10, Vol.29, p.viii101-viii101

2018

Volltextzugriff (PDF)

Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802)

Annals of oncology, 2009-07, Vol.20 (7), p.1210-1215

2009

Volltextzugriff (PDF)

1 – 25 von 5.188

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(3.896)
Mit Volltextzugriff
(4.194)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(2.778)
Life Sciences & Biomedicine
(1.810)
Humans
(1.487)
Male
(1.103)
Biological And Medical Sciences
(1.009)
Female
(968)
Physical Sciences
(801)
Animals
(781)
Medical Sciences
(739)
Middle Aged
(730)
Adult
(605)
Aged
(577)
Technology
(448)
Physics
(416)
Exact Sciences And Technology
(326)
Oncology
(321)
Fundamental And Applied Biological Sciences. Psychology
(312)
Rats
(288)
Chemistry
(282)
Mice
(246)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(8)
... seit 90 Tagen
(13)

Menü

Weitere Dienste

Einstellungen

OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

Identifying well-bleached quartz using the different bleaching rates of quartz and feldspar luminescence signals

A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer

Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer

Multicenter Randomized Open-Label Phase II Clinical Study Comparing Outcomes of NK105 and Paclitaxel in Advanced or Recurrent Breast Cancer

Safety profile and effectiveness of alectinib in the real-world surveillance study of 1251 Japanese patients with ALK-positive non-small cell lung cancer

A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer

Chaotic block ciphers: from theory to practical algorithms

Substrate Specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM Efflux Pumps in Pseudomonas aeruginosa

The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study

Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: Updated results from a phase I/II trial

346P Phase I study of the liposomal formulation of eribulin (E7389-LF): Results from the HER2-negative breast cancer expansion

Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial

Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy

Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1)

Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples

Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari)

A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer

A phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in elderly patients with advanced stage HER2-positive breast cancer (JCOG1607 HERB TEA study)

Distant disease-free survival (DDFS) according to response category in neoadjuvant endocrine therapy (NET): 6-year analysis in phase III NEOS trial

Abstract PD1-03: Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: Updated results of a phase 1/2 trial

Effect of dose timing on the blood concentration of lapatinib in patients with breast cancer

Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3

Clinical efficacy of eribulin as first- or second-line treatment for patients with recurrent HER2-negative breast cancer: A phase II randomized study (JBCRG-19)

Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802)

Suchergebnisse filtern